| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 20.30 | -97 |
| Intrinsic value (DCF) | 767.76 | 15 |
| Graham-Dodd Method | 7.50 | -99 |
| Graham Formula | 9.70 | -99 |
Camurus AB (publ) is a Sweden-based pharmaceutical company specializing in the development and commercialization of innovative medicines for severe and chronic conditions. Operating globally, including in Europe, the U.S., Australia, and Japan, Camurus focuses on addressing unmet medical needs in areas such as opioid dependence, chronic pain, and rare diseases. Its flagship product, Buvidal, is a long-acting buprenorphine injection for opioid use disorder, while its pipeline includes promising candidates like CAM2038 (chronic pain), CAM2029 (acromegaly and neuroendocrine tumors), and CAM4072 (genetic obesity disorders). Leveraging its proprietary FluidCrystal® drug delivery technology, Camurus enhances drug efficacy and patient compliance through sustained-release formulations. With a strong R&D focus and strategic partnerships, the company is well-positioned in the growing specialty pharmaceuticals market. Camurus, founded in 1991 and headquartered in Lund, Sweden, trades on the London Stock Exchange under the ticker 0RD1.L.
Camurus presents an attractive investment opportunity due to its niche focus on high-need therapeutic areas and innovative drug delivery technologies. The company’s revenue growth is supported by Buvidal’s expanding market penetration and a robust pipeline targeting chronic and rare diseases. With a solid cash position (SEK 2.85 billion) and minimal debt (SEK 17 million), Camurus maintains financial flexibility for R&D and commercialization. However, risks include clinical trial uncertainties, regulatory hurdles, and competition in opioid dependence treatments. The stock’s low beta (0.577) suggests relative stability, but reliance on pipeline success and international expansion could introduce volatility. Investors should weigh its growth potential against sector-specific risks.
Camurus competes in the specialty pharmaceuticals market, differentiating itself through its FluidCrystal® technology, which enables long-acting injectable formulations. This provides a competitive edge in patient adherence and dosing convenience, particularly in opioid use disorder (OUD) and chronic pain. Buvidal competes with Indivior’s Sublocade, but Camurus’s monthly and weekly formulations offer broader dosing flexibility. In acromegaly and neuroendocrine tumors, CAM2029 could challenge Novartis’s Sandostatin LAR, pending phase III success. The company’s rare disease pipeline (e.g., CAM4072 for genetic obesity) positions it against Rhythm Pharmaceuticals’ Imcivree, though Camurus’s candidate is earlier-stage. While Camurus lacks the scale of large pharma, its targeted approach and partnerships (e.g., with Braeburn for U.S. commercialization) enhance its market access. Competitors with broader portfolios may outspend on marketing, but Camurus’s innovation in drug delivery sustains its niche appeal.